These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Biomechanical evaluation of the pathophysiologic developmental mechanisms of mitral valve prolapse: effect of valvular morphologic alteration. Choi A; McPherson DD; Kim H Med Biol Eng Comput; 2016 May; 54(5):799-809. PubMed ID: 26307201 [TBL] [Abstract][Full Text] [Related]
7. Gross and histological features of excised portions of posterior mitral leaflet in patients having operative repair of mitral valve prolapse and comments on the concept of missing (= ruptured) chordae tendineae. Roberts WC; Vowels TJ; Ko JM; Hebeler RF J Am Coll Cardiol; 2014 Apr; 63(16):1667-74. PubMed ID: 24316086 [TBL] [Abstract][Full Text] [Related]
8. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. Sainger R; Grau JB; Branchetti E; Poggio P; Seefried WF; Field BC; Acker MA; Gorman RC; Gorman JH; Hargrove CW; Bavaria JE; Ferrari G J Cell Physiol; 2012 Jun; 227(6):2595-604. PubMed ID: 22105615 [TBL] [Abstract][Full Text] [Related]
9. Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation. Driesbaugh KH; Branchetti E; Grau JB; Keeney SJ; Glass K; Oyama MA; Rioux N; Ayoub S; Sacks MS; Quackenbush J; Levy RJ; Ferrari G J Mol Cell Cardiol; 2018 Feb; 115():94-103. PubMed ID: 29291394 [TBL] [Abstract][Full Text] [Related]
10. A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. Ibarrola J; Garcia-Peña A; Matilla L; Bonnard B; Sádaba R; Arrieta V; Alvarez V; Fernández-Celis A; Gainza A; Navarro A; Alvarez de la Rosa D; Rossignol P; Jaisser F; López-Andrés N Circ Res; 2020 Jul; 127(3):e80-e93. PubMed ID: 32329663 [TBL] [Abstract][Full Text] [Related]
11. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Ng CM; Cheng A; Myers LA; Martinez-Murillo F; Jie C; Bedja D; Gabrielson KL; Hausladen JM; Mecham RP; Judge DP; Dietz HC J Clin Invest; 2004 Dec; 114(11):1586-92. PubMed ID: 15546004 [TBL] [Abstract][Full Text] [Related]
12. TGF-β signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Hagler MA; Hadley TM; Zhang H; Mehra K; Roos CM; Schaff HV; Suri RM; Miller JD Cardiovasc Res; 2013 Jul; 99(1):175-84. PubMed ID: 23554457 [TBL] [Abstract][Full Text] [Related]
13. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data. Hulin A; Deroanne C; Lambert C; Defraigne JO; Nusgens B; Radermecker M; Colige A Cardiovasc Pathol; 2013; 22(4):245-50. PubMed ID: 23261354 [TBL] [Abstract][Full Text] [Related]
14. Transesophageal echocardiographic assessment of the contribution of intrinsic tissue thickness to the appearance of a thick mitral valve in patients with mitral valve prolapse. Louie EK; Langholz D; Mackin WJ; Wallis DE; Jacobs WR; Scanlon PJ J Am Coll Cardiol; 1996 Aug; 28(2):465-71. PubMed ID: 8800127 [TBL] [Abstract][Full Text] [Related]
15. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Geirsson A; Singh M; Ali R; Abbas H; Li W; Sanchez JA; Hashim S; Tellides G Circulation; 2012 Sep; 126(11 Suppl 1):S189-97. PubMed ID: 22965982 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration. Tan K; Markby G; Muirhead R; Blake R; Bergeron L; Fici G; Summers K; Macrae V; Corcoran B PLoS One; 2019; 14(8):e0221126. PubMed ID: 31415646 [TBL] [Abstract][Full Text] [Related]
17. FOXC1 and FOXC2 Ablation Causes Abnormal Valvular Endothelial Cell Junctions and Lymphatic Vessel Formation in Myxomatous Mitral Valve Degeneration. Tan C; Ge ZD; Kurup S; Dyakiv Y; Liu T; Muller WA; Kume T Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1944-1959. PubMed ID: 38989578 [TBL] [Abstract][Full Text] [Related]
19. Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease. Hulin A; Moore V; James JM; Yutzey KE Cardiovasc Res; 2017 Jan; 113(1):40-51. PubMed ID: 28069701 [TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological features of degenerative mitral valve disease: billowing mitral leaflet versus fibroelastic deficiency. Matsumaru I; Eishi K; Hashizume K; Kawano H; Tsuneto A; Hayashi T Ann Thorac Cardiovasc Surg; 2014; 20(6):987-94. PubMed ID: 24284503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]